These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 12099170)

  • 1. Morphine oral--Elan Corporation. Avinza.
    Drugs R D; 2002; 3(3):208-9. PubMed ID: 12099170
    [No Abstract]   [Full Text] [Related]  

  • 2. Avinza Elan.
    Semenchuk MR
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1369-72. PubMed ID: 12498014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions--the ACCPT Study.
    Adams EH; Chwiecko P; Ace-Wagoner Y; Mangefrida B; Duerden ME; Perdikis GC; Kunkel FA; Ghalie R
    Pain Pract; 2006 Dec; 6(4):254-64. PubMed ID: 17129306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery.
    Skak N; Elhauge T; Dayno JM; Lindhardt K
    J Opioid Manag; 2017; 13(6):465-472. PubMed ID: 29308592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous intravenous narcotic infusions for cancer pain.
    Cohen MH; Johnston-Anderson A; Krasnow SH; Wadleigh RG
    Cancer Invest; 1993; 11(2):169-73. PubMed ID: 8462017
    [No Abstract]   [Full Text] [Related]  

  • 6. Kollidon SR colloidal particles as vehicles for oral morphine delivery in pain treatment.
    Arias JL; Gómez-Gallo A; Delgado AV; Ruiz MA
    Colloids Surf B Biointerfaces; 2009 May; 70(2):207-12. PubMed ID: 19167868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation development and stability testing of oral morphine solution utilizing preformulation approach.
    Preechagoon D; Sumyai V; Tontisirin K; Aumpon S; Pongjanyakul T
    J Pharm Pharm Sci; 2005 Aug; 8(2):362-9. PubMed ID: 16124948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphine pharmacokinetics and analgesia after oral administration.
    Hanks GW
    Postgrad Med J; 1991; 67 Suppl 2():S60-3. PubMed ID: 1758818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyoxyethylene fatty acid esters as potential promotors of transdermal absorption for morphine hydrochloride and sulphate.
    Samczewska G; Piechota-Urbańska M; Kołodziejska J
    Polim Med; 2006; 36(2):17-32. PubMed ID: 17022153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.
    Gourlay GK
    Clin Pharmacokinet; 1998 Sep; 35(3):173-90. PubMed ID: 9784932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The conversion challenge: from intrathecal to oral morphine.
    Sylvester RK; Lindsay SM; Schauer C
    Am J Hosp Palliat Care; 2004; 21(2):143-7. PubMed ID: 15055516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and in vitro evaluation of a controlled release formulation to produce wide dose interval morphine tablets.
    Holgado MA; Iruin A; Alvarez-Fuentes J; Fernández-Arévalo M
    Eur J Pharm Biopharm; 2008 Oct; 70(2):544-9. PubMed ID: 18588973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic equivalence of i.m. and p.o. administration of morphine--1:3 or 1:6?
    Kaiko RF
    J Palliat Care; 1988 May; 4(1-2):64-6. PubMed ID: 2459360
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential pharmacokinetics and the brain distribution of morphine and ephedrine constitutional isomers in rats after oral administration with Keke capsule using rapid-resolution LC-MS/MS.
    Song Y; Su D; Lu T; Mao C; Ji D; Liu Y; Wei B; Fan R
    J Sep Sci; 2014 Feb; 37(4):352-9. PubMed ID: 24318005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic equivalence of oral and subcutaneous/intramuscular morphine sulphate in cancer patients.
    Twycross RG
    J Palliat Care; 1988 May; 4(1-2):67-8. PubMed ID: 2459361
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacokinetic effects in morphine toxicity, with case examples].
    Morant R; Senn HJ
    Schweiz Rundsch Med Prax; 1991 Jun; 80(26):719-22. PubMed ID: 1862260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bioavailability of morphine after oral administration as retard tablets].
    Dittrich P; Semmelrock J; Wolf G; Beubler E
    Wien Klin Wochenschr; 1996; 108(5):147-52. PubMed ID: 8901129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphine and alternative opioids in cancer pain: the EAPC recommendations.
    Hanks GW; Conno F; Cherny N; Hanna M; Kalso E; McQuay HJ; Mercadante S; Meynadier J; Poulain P; Ripamonti C; Radbruch L; Casas JR; Sawe J; Twycross RG; Ventafridda V;
    Br J Cancer; 2001 Mar; 84(5):587-93. PubMed ID: 11237376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abuse-deterrent opioid formulations.
    Med Lett Drugs Ther; 2015 Aug; 57(1476):119-21. PubMed ID: 26305522
    [No Abstract]   [Full Text] [Related]  

  • 20. Morphine bioavailability from a topical gel formulation in volunteers.
    Paice JA; Von Roenn JH; Hudgins JC; Luong L; Krejcie TC; Avram MJ
    J Pain Symptom Manage; 2008 Mar; 35(3):314-20. PubMed ID: 18178369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.